Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

150 questions · 150 findings · 48 reviews

No studies found 19 · 12.7%GRADE not reported 21 · 14%Very low 40 · 26.7%Low 39 · 26%Moderate 23 · 15.3%High 8 · 5.3%

Oral diazepam vs placebo

Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral diclofenac sodium (NSAID) vs placebo

Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral cyclobenzaprine (muscle relaxant) vs placebo

Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Naproxen vs placebo

Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral celecoxib (COX-2 inhibitor) vs placebo

Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Piroxicam vs placebo

Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral prazepam (benzodiazepine) vs placebo

Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam

Number of participants with any adverse event (primary tolerability outcome) · participants with moderate to severe hand eczema

Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with vehicle foam (moderate certainty).

1 finding from 1 review

Intervention not reported

Discontinuation of study drug due to adverse events · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Topical capsaicin vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral gabapentin vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral glucosamine hydrochloride/chondroitin sulphate vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral clonazepam (benzodiazepine) vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Prebiotic vs placebo

Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)

It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).

1 finding from 1 review

Tacrolimus 0.1% vs vehicle

Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).

1 finding from 1 review

Abrupt discontinuation deprescribing vs continued use

Adverse drug withdrawal events ‐ relapse (endoscopic findings) · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)

It is very uncertain whether abrupt discontinuation deprescribing changes adverse drug withdrawal events ‐ relapse (endoscopic findings) compared with continued use (very low certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 30 mg vs placebo

Adverse effects: headache · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 30 mg leads to higher primary: adverse events ‐ headache Folluw‐up: 48 weeks to 72 weeks compared with placebo (high certainty).

1 finding from 1 review

On‐demand deprescribing vs continued use

Adverse drug withdrawal events ‐ esophagitis (endoscopic findings) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years

On‐demand deprescribing may leads to higher adverse drug withdrawal events ‐ esophagitis (endoscopic findings) compared with continued use (low certainty).

1 finding from 1 review